Rchr
J-GLOBAL ID：200901058343987915
Update date: Jun. 06, 2020
Miki Takami
ミキ タカミ | Miki Takami
Contact this researcher
You can send email directly to the researcher.
Affiliation and department：
Osaka City University Graduate School of Medicine
About Osaka City University Graduate School of Medicine
Search "Osaka City University Graduate School of Medicine"
Detailed information
Research field (1)：
Internal medicine - General
Research keywords (1)：
Geriatric medicine
Research theme for competitive and other funds (4)：
痴呆症の臨床的研究
骨粗鬆症の臨床的研究
Clinical research of Dimentia
Clinical research of Osteoporosis
MISC (8)：
H Shimada, M Kihara, S Kosaka, H Ikeda, K Kawabata, T Tsutada, T Miki. Comparison of SSR and QSART in early diabetic neuropathy - the value of length-dependent pattern in QSART. AUTONOMIC NEUROSCIENCE-BASIC & CLINICAL. 2001. 92. 1-2. 72-75
Y Takaishi, T Miki, Y Nishizawa, H Morii. Clinical effect of etidronate on alveolar pyorrhoea associated with chronic marginal periodontitis: Report of four cases. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH. 2001. 29. 4. 355-365
Clinical evaluation of the Elecsys Β-CrossLaps serum Assay, a new assay for degaradation products of type 1 collagen C-telopeptides. Clinical Chemistry. 2001. 47. 8. 1410-1414
骨粗鬆症の薬物療法の進め方. 薬局. 2000. 51. 419-424
E Ishimura, Y Nishizawa, M Inaba, N Matsumoto, M Emoto, T Kawagishi, S Shoji, S Okuno, M Kim, T Miki, et al. Serum levels of 1,25-dihydroxyvitamin D, 24,25-dihydroxyvitamin D, and 25-hydroxyvitamin D in nondialyzed patients with chronic renal failure. KIDNEY INTERNATIONAL. 1999. 55. 3. 1019-1027
ｍore...
Books (5)：
Primary osteoporosis. in Calcium in Internal Medicine. Springer Verlay. London.
Calcium in Internal Medicine: Springer Verlay, London 2001
高齢者透析
医薬ジャーナル社、透析医学の文化と技術 1999
薬物治療<ステロイド骨粗鬆症の診断と治療>
メヂカルレビユー社、ステロイド骨粗鬆症の診断と治療 1999
(1)骨代謝マーカによる評価法ー総論、(2)骨形成マーカー (3)骨代謝マーカーによる効果判定
ライフサイエンス出版、最新骨粗鬆症 1999
骨代謝マーカー手引き
ライフサイエンス出版、骨代謝マーカー手引き 1998
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in
researchmap
.
For details, see here
.
Return to Previous Page
TOP
BOTTOM
